In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Pharmaceutica Inc.

Division of Johnson & Johnson

Latest From Janssen Pharmaceutica Inc.

UK Life-Sciences Sector Deal Brings Life And Funding To Industrial Strategy

The next step in the UK government's life-science strategy, the Life Sciences Sector Deal, was issued today, setting out a blueprint of government-support mechanisms and private investment across the whole of the sector. The deal, signaled yesterday at UK HealthTech 2017, seeks to maximize the potential of medtech and pharma businesses, and exploit the value of the NHS.

United Kingdom Market Access

What's Best For A Pharma CEO, An MBA Or A Medical Degree?

When it was announced in September that Novartis's chief medical officer Vas Narashimhan is going to replace Joseph Jimenez as the Swiss major's chief executive in February 2018, much was made of the fact that one of the world's biggest pharmaceutical companies will be led by a scientist.

Scrip 100 Business Strategies

Janssen Pilot Speeds Up African Approvals As Harmonization Project Expands

A recent pilot involving Janssen Pharmaceutica has shown that drug approval times were reduced from a median of 20 months to seven months in a set of sub-Saharan African countries using a new “collaborative registration procedure” as part of the African Medicines Regulatory Harmonization initiative. In part 2 of this article on the AMRH, we look at the results of the pilot, how the initiative is being expanded to include more countries and to cover clinical trials and pharmacovigilance, and how far efforts to set up an African Medicines Agency by 2018 might bear fruit.

Middle East and Africa Drug Approval Standards

Medivir Narrows Research Strategy To Cancer And Infectious Diseases

Sweden's Medivir drops neuropathic pain research to focus on oncology and infectious diseases while streamlining its R&D process by partnering with India’s GVK BIO, in a bid to cut costs and raise flexibility.

BioPharmaceutical Sweden
See All

Company Information